{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-22-001230","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2022-09-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.967344+00:00","generated_at":"2026-06-23T17:45:26.799831+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arcturus receives $63.2M BARDA award to develop self-amplifying mRNA pandemic flu vaccine","bullets":["BARDA provides up to $63.2 million over three years for pandemic influenza vaccine development using STARR self-amplifying mRNA platform.","Funding covers preclinical through Phase 1 clinical studies, including manufacturing and regulatory support.","Candidate is lower-dose, freeze-dried vaccine; Arcturus' platform has been administered to over 10,000 individuals for SARS-CoV-2.","Contract is terminable by BARDA at any time for convenience; no purchase of vaccine in scope.","Award part of U.S. government's National Strategy for Pandemic Influenza to bolster pandemic preparedness."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-22-001230","json":"https://secwatch.observer/filing/0001193805-22-001230.json","markdown":"https://secwatch.observer/filing/0001193805-22-001230.md","text":"https://secwatch.observer/filing/0001193805-22-001230.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380522001230/0001193805-22-001230-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380522001230/e621904_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T17:45:26.799831+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}